Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
| Autor: | Parto Sabetrasekh, Saleh Sandoughdaran, Ladan Mohammadi Yeganeh, Fatemeh Nasrollahi, Sara Khoshroo, Parastoo Hajian, Pegah Bikdeli, Hamid Reza Mirzaei, Sepideh Jafari Naeini, Parisa Sabetrasekh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Cyclophosphamide Anthracycline Article Subject medicine.medical_treatment chemistry.chemical_compound Breast cancer Internal medicine medicine Pharmacology (medical) RC254-282 Chemotherapy business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Regimen Docetaxel Paclitaxel chemistry business medicine.drug Epirubicin Research Article |
| Zdroj: | International Journal of Breast Cancer International Journal of Breast Cancer, Vol 2021 (2021) |
| ISSN: | 2090-3170 |
| DOI: | 10.1155/2021/6653265 |
| Popis: | Background/Aims. The anthracycline and taxane-based chemotherapy regimens are the standard adjuvant treatment of node-positive breast cancer patients. Although it was believed that docetaxel and paclitaxel are similarly effective as adjuvant treatment in node-positive breast cancer, recent studies report that weekly paclitaxel is superior to weekly and triweekly docetaxel schedules in terms of overall survival (OS) and disease-free survival (DFS). However, to the best of our knowledge, no study has compared weekly paclitaxel with a dose-dense regimen of docetaxel. The current study is aimed at evaluating the outcome of women with node-positive breast cancer who had received weekly paclitaxel compared with those treated with dose-dense docetaxel. Methods. This study included patients from two prospective studies conducted in our institute from April 2007 to March 2009. Ninety-one women with axillary lymph node-positive breast cancer who had received four cycles of dose-dense epirubicin and cyclophosphamide were treated with either weekly paclitaxel (80 mg/m2) for 12 doses or biweekly docetaxel (75 mg/m2) for four cycles. Results. After a median follow-up of 88 and 109 months, 11 (23.4%) and 10 (22.7%) patients had experienced disease recurrence ( p = 0.16 ), while 10 (21.3%) and 5 (11.4%) patients had died in the paclitaxel and docetaxel arm, respectively ( p = 0.56 ). No significant difference could be seen in 5-year DFS or OS among groups (HR: 0.58; 95% CI: 0.19–1.81, p = 0.35 ; HR: 0.58; 95% CI: 0.19–1.81, p = 0.35 , respectively). Conclusion. In conclusion, both evaluated adjuvant chemotherapy regimens have comparable effectiveness regarding DFS and OS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|